- Home
- BGI vs CARA Comparison
BGI vs CARA Comparison
Compare BGI & CARA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BGI
- CARA
- Stock Information
- Founded
- BGI 1879
- CARA 2004
- Country
- BGI Canada
- CARA United States
- Employees
- BGI N/A
- CARA N/A
- Industry
- BGI
- CARA Biotechnology: Pharmaceutical Preparations
- Sector
- BGI
- CARA Health Care
- Exchange
- BGI Nasdaq
- CARA Nasdaq
- Market Cap
- BGI 21.8M
- CARA 23.6M
- IPO Year
- BGI 2005
- CARA 2014
- Fundamental
- Price
- BGI $1.29
- CARA $5.10
- Analyst Decision
- BGI
- CARA Hold
- Analyst Count
- BGI 0
- CARA 3
- Target Price
- BGI N/A
- CARA $12.00
- AVG Volume (30 Days)
- BGI 71.4K
- CARA 10.4K
- Earning Date
- BGI 11-27-2024
- CARA 05-12-2025
- Dividend Yield
- BGI N/A
- CARA N/A
- EPS Growth
- BGI N/A
- CARA N/A
- EPS
- BGI N/A
- CARA N/A
- Revenue
- BGI $131,596,265.00
- CARA $7,137,000.00
- Revenue This Year
- BGI N/A
- CARA N/A
- Revenue Next Year
- BGI N/A
- CARA N/A
- P/E Ratio
- BGI N/A
- CARA N/A
- Revenue Growth
- BGI 4.01
- CARA N/A
- 52 Week Low
- BGI $0.93
- CARA $2.71
- 52 Week High
- BGI $3.42
- CARA $11.39
- Technical
- Relative Strength Index (RSI)
- BGI 57.94
- CARA 49.07
- Support Level
- BGI $1.03
- CARA $4.88
- Resistance Level
- BGI $1.24
- CARA $5.15
- Average True Range (ATR)
- BGI 0.09
- CARA 0.26
- MACD
- BGI 0.02
- CARA -0.04
- Stochastic Oscillator
- BGI 78.79
- CARA 25.89
About BGI Birks Group Inc.
Birks Group Inc is a part of the leisure industry. The company designs, develops, produces, and retails fine jewelry, timepieces, and gifts. Its operating segments include Retail and Other. The company generates maximum revenue from the Retail segment. Its retail segment consists of retail operations whereby it operates stores in Canada under the Maison Birks, Brinkhaus, Graff, and Patek Phillippe brands. The other segment consists mainly of wholesale business, e-commerce business, and gold exchange business.
About CARA Cara Therapeutics Inc.
Cara Therapeutics Inc is a development-stage biotechnology company involved in the development of novel therapeutics to treat human diseases associated with inflammation, pain, and pruritus. Cara's CR845, aims to treat acute pain and pruritus. This patented compound has analgesic, anti-inflammatory, and antipruritic properties that can be used for multiple therapeutic applications. Additionally, Cara's objective is to use its proprietary drug-screening technology to develop a future pipeline of first-in-class molecules with analgesic and anti-inflammatory features.